Dana-Farber’s $15M Case: Admissions, Breakdown, and Response

The Dana-Farber $15 million settlement, announced by the Department of Justice on December 16, 2025, resolved False Claims Act allegations that researchers at the Boston cancer institute used federal grant money to produce studies containing falsified or manipulated data. The agreement ended a qui tam case brought by Welsh molecular biologist Sholto David, who received $2,625,000 as his whistleblower share. It stands as one of the largest False Claims Act recoveries tied specifically to image manipulation in scientific research.¹

What Dana-Farber Admitted

Unlike many False Claims Act settlements in which the defendant admits nothing, Dana-Farber made specific factual admissions. The institute acknowledged that researchers used funds from six NIH grants to conduct research resulting in 14 publications that contained “misrepresented and/or duplicated images and data.” The manipulations included reusing images to represent different experimental conditions, duplicating images across different mice or timepoints, and rotating, magnifying, or stretching images.¹

Dana-Farber also admitted that a supervising researcher “failed to exercise sufficient oversight” of the scientists who produced those publications. The papers appeared in journals including Leukemia, Blood, Blood Advances, and Clinical Cancer Research between 2015 and 2024.² A second researcher was acknowledged to have received four additional NIH grants after submitting applications that cited a 2015 Nature Medicine article without disclosing that the paper contained misrepresented or duplicated images. That article received two image-related corrections in 2024 but was not retracted.³

Importantly, the settlement did not include an admission that anyone at the institute committed intentional fraud.⁴

How the $15 Million Breaks Down

Dana-Farber paid $15 million to the United States, of which $8,571,428.57 was designated as restitution. The balance accrued interest at 4.375% annually from August 27, 2025, until payment, and the institute had to pay within 30 days of the agreement’s effective date. David received 17.5% of the recovery, or $2,625,000, as his whistleblower share. Dana-Farber separately paid $328,498.53 to cover his attorneys’ fees.⁵

The agreement contained no confidentiality clause. Dana-Farber also agreed that all costs related to the investigation and settlement were “unallowable costs” that could not be charged to any federal contract or grant, and that any such costs already submitted for federal payment had to be identified and repaid within 90 days. The government reserved the right to pursue individual liability separately.⁵

Who the Researchers Were

The DOJ’s formal documents referred only to “Researcher 1” and “Researcher 2.” Reporting identified them as Kenneth C. Anderson, director of the LeBow Institute for Myeloma Therapeutics, and physician-scientist Ruben Carrasco. Anderson was the senior author on 12 of the 14 implicated papers and has accumulated 10 retractions in the Retraction Watch database, the earliest dating to 2008.³ The settlement documents did not report specific disciplinary actions against him, and no public statement from Anderson appeared in the reporting on the settlement.

David’s original complaint had encompassed 95 studies involving several other Dana-Farber leaders, including then-CEO Laurie Glimcher, Chief Operating Officer William Hahn, and Senior Vice President for Experimental Medicine Irene Ghobrial. None of those individuals were named in the final settlement, and available reporting does not indicate that any faced individual consequences as a result of the matter.⁶

How the Case Started

The controversy began on January 2, 2024, when Sholto David published a guest post on the blog For Better Science titled “Dana-Farberications at Harvard University.” David, who has commented on more than 6,000 papers on the post-publication review site PubPeer, identified what he described as duplicated, spliced, stretched, and recolored images across dozens of studies authored by senior Dana-Farber scientists.⁷

Within three weeks, Dana-Farber publicly acknowledged the concerns and announced it would ask journals to retract six research papers and correct 31 others.⁸ Barrett Rollins, the institute’s research integrity officer, said the image discrepancies appeared “credible” but cautioned that “the presence of image discrepancies in a paper is not evidence of an author’s intent to deceive.”⁹

On April 22, 2024, David and his attorneys, Eugenie Reich and Gregg Shapiro, filed a qui tam complaint under seal in the U.S. District Court for the District of Massachusetts. United States ex rel. Sholto David v. Dana-Farber Cancer Institute, Inc., No. 2:24-cv-11059-WGY, alleged that Dana-Farber violated the False Claims Act by submitting false certifications to the NIH and spending grant funds on research that produced publications with manipulated data.⁵ The complaint remained sealed for roughly 20 months, exceptionally fast for a qui tam action, while David’s legal team spent hundreds of hours supporting the government’s investigation.¹⁰

Dana-Farber’s Cooperation and Response

The DOJ credited Dana-Farber for cooperating extensively during the investigation. According to the settlement, the institute voluntarily disclosed additional allegations of research misconduct beyond those in the original complaint, produced materials without a subpoena, summarized voluminous records for investigators, and sought to resolve the matter quickly.¹

Benjamin Ebert, who became Dana-Farber’s president and CEO after Glimcher’s departure, said the institute had “developed and implemented a number of initiatives to enhance our research integrity efforts, improve data hygiene, and prevent avoidable errors in scientific papers.” He added: “Scientific errors do not meet the high standards that Dana-Farber expects from its researchers, and we act quickly and proactively to address them when they occur.”⁴ The settlement itself did not detail the specific nature of those remedial measures.

How the Settlement Fits Into Research Fraud Enforcement

The Dana-Farber recovery sits within a growing body of False Claims Act enforcement targeting federally funded research. The most prominent precedent is Duke University’s $112.5 million settlement in 2019 over fabricated data in federal grant applications.¹¹

What made Dana-Farber distinctive was the role of an outside data sleuth as the whistleblower. Traditional qui tam cases typically involve institutional insiders. David built his case entirely from publicly available information, demonstrating that the False Claims Act’s whistleblower provisions do not require the complainant to come from within the organization. After the settlement, he said he hoped the outcome “will encourage the research community to take scientific rigor seriously,” adding: “The rest of the money will go back to the NIH and they can spend it on research. I think it is a positive outcome.”⁴

Brett Shumate, assistant attorney general of the DOJ’s Civil Division, framed the settlement as a warning to the broader research community. “Today’s settlement demonstrates that the Department of Justice will pursue grantees that undermine the integrity of federal funding decisions by failing to use research funds appropriately or by failing to abide by grant awards’ terms and conditions,” he said.⁴

1
U.S. Department of Justice. Dana-Farber Cancer Institute Agrees To Pay $15M To Settle Fraud Allegations Related to Scientific Research Grants
2
Chemical & Engineering News. Dana-Farber Settles Lawsuit Alleging Misconduct
3
Retraction Watch. Dana-Farber Settlement False Claims Act Image Manipulation
4
STAT News. Dana-Farber $15 Million Settlement Manipulated Data
5
U.S. Department of Justice. Settlement Agreement, U.S. ex rel. Sholto David v. Dana-Farber Cancer Institute
6
Science. Errors Found in Dozens of Papers by Top Scientists at Dana-Farber Cancer Institute
7
Science. Misconduct Sleuth Wins $2.63 Million in Major Cancer Institute $15 Million Settlement
8
The BMJ. Dana-Farber Cancer Institute to Retract and Correct Research Papers
9
WBUR. Cancer Institute Data Fabrication Manipulation
10
Gregg Shapiro Law. Eugenie Reich, Gregg Shapiro Announce $15 Million False Claims Act Grant Fraud Settlement With Dana-Farber
11
Southwestern Law School. FCA Scope Illustrated in Recent Higher Education Actions